|
new IPO for a very old company.... thread initiated to begin the usual collection of background info. Please cut and paste from the prospectus as you cruise it and find items of interest.......
Thursday April 20, 10:14 am Eastern Time
Company Press Release
SOURCE: Packard BioScience Company
Packard BioScience Raises $108 Million in Initial
Public Offering of Common Stock
MERIDEN, Conn., April 20 /PRNewswire/ -- Packard BioScience Company (Nasdaq: PBSC - news) today announced an
initial public offering of 12,000,000 shares of its common stock at an initial public offering price of $9.00 per share. All of the
shares are being offered by the Company. The shares will trade on the Nasdaq National Market under the symbol ``PBSC.'
Merrill Lynch & Co., Chase H&Q, Robert W. Baird & Co., Banc of America Securities LLC, and Thomas Weisel Partners
LLC are acting as the underwriters for the offering. A substantial portion of the net proceeds from the offering will be used to
reduce Packard's existing indebtedness and to increase spending associated with research and development, new product
development, enhancement of existing products and strategic collaborations and acquisitions.
Packard BioScience Company is a leading global developer, manufacturer and marketer of instruments and related
consumables and services for use in the life sciences research and nuclear industries. The Company is primarily focused on the
rapidly growing areas of drug discovery, genomics and biochip analysis and is continuing to develop integrated platforms based
on a wide range of technologies and instrumentation. These platforms are designed to support the industrialization of drug
discovery by bringing the benefits of miniaturization, automation and ultra-high throughput analysis to these areas. Packard's
experience in working in more than 60 countries with market leading customers, has allowed the Company to establish a
worldwide leadership position in many of its primary product categories, with well recognized brand names and a reputation for
high quality, reliable instruments.
Copies of the final prospectus related to the offering may be obtained from the following: Merrill Lynch & Co., World Financial
Center, North Tower, New York, New York 10281, (212) 449-1000; Chase H&Q, 230 Park Avenue, New York, New
York 10169, (212) 207-1400; Robert W. Baird & Co., 777 East Wisconsin Avenue, 28th floor, Milwaukee, Wisconsin,
53202, (414) 765-3500; Banc of America Securities LLC, 9 West 57th Street, New York, New York 10019, (212)
583-8321 or; Thomas Weisel Partners LLC, 390 Park Avenue, 16th floor, New York, New York, 10022, (212) 271-3700.
Contact: Michael Zebarth, Vice President, Corporate Communications and Investor Relations of Packard BioScience
Company, 203-639-2340; or Miriam Weber, ext. 352 (investors) Matthew Knight, ext. 271 (media), both of Noonan-Russo
Communications, Inc., 212-696-4455
SOURCE: Packard BioScience Company |
|
